Novel transcript, antisense to RFTN1 (ENSG00000272529)

This target represents a long non-coding RNA molecule naturally transcribed antisense to the RFTN1 (Raftlin, lipid raft linker 1) gene. Natural antisense transcripts regulate the expression of their corresponding sense genes through multiple mechanisms, including transcriptional interference, double-stranded RNA formation, RNA masking, RNA interference, and modulation of chromatin structure[1][2][3]. While some antisense transcripts are known to play roles in disease pathogenesis, especially in cancer and neurodegenerative conditions, there are currently no data implicating the RFTN1 antisense transcript in any specific disease or as a therapeutic target[1][2]. No interacting drugs, clinical biomarkers, or safety concerns have been established for this transcript. Key details: - **Natural antisense transcripts** are a class of lncRNAs generated from the opposite strand of known coding genes and participate broadly in the *regulation of gene expression* at levels ranging from chromatin remodeling to mRNA stability[1][3]. - While some antisense transcripts have confirmed or potential therapeutic relevance (e.g., FOXP4-AS1, FAM83C-AS1), each needs to be evaluated individually; most NATs, including the one corresponding to ENSG00000272529, lack experimental or clinical evidence supporting a role as a drug target[1]. - This entity should **not be considered a canonical therapeutic target** such as a receptor, transporter, or enzyme, and should be classified as a long non-coding RNA. In summary: - **Not a classic therapeutic target**; should be considered a lncRNA with potentially regulatory but unvalidated biological significance[1][2][3]. - **No evidence of drug interaction, biomarker role, or disease involvement** specific to RFTN1 antisense transcript.

Other names

RFTN1-ASantisense to RFTN1